This content is protected against AI scraping.
The U.S. House of Representatives just passed “Tyler’s Law” (H.R. 2004), a bill that directs the Department of Health and Human Services (HHS) to study how emergency rooms test for drugs during overdose cases. While inspired by 19-year-old Tyler Shamash—who died from an undetected fentanyl overdose in 2018—the House text specifically mandates that HHS look into how often ERs test for marijuana alongside fentanyl, cocaine, opiates, amphetamines, and PCP. Under this proposal, HHS has one year to assess screening frequency for cannabis and other drugs, evaluate the associated costs, and analyze impacts on patient privacy and doctor-patient trust.
However, the Senate’s version creates a major distinction around cannabis. Passed in March, the Senate companion bill explicitly stripped out references to marijuana and other named drugs, replacing them with broader “controlled substances” language and extending HHS’s study timeline from one to three years. The House and Senate must now reconcile these conflicting details—specifically whether marijuana remains explicitly named—before a final version can reach President Donald Trump.
Meanwhile, marijuana’s impact on emergency care is the sole focus of a separate Senate bill, the Marijuana Impact on Medicaid Act of 2026. Introduced by Sens. Ted Budd (R-NC) and Pete Ricketts (R-NE), this measure would force HHS to track exact federal and state Medicaid dollars spent on ER visits, inpatient stays, and outpatient hospital care related to marijuana use. Together, these proposals highlight a growing federal push to measure how ERs handle cannabis testing and quantify the financial footprint of marijuana-related hospital visits.
This is a summary.
Please read the original article: House Passes Bill Requiring Feds To Track Testing For Marijuana And Other Drugs In Hospital Emergency Rooms
Original article written by Tom Angell. Published on September 16, 2026 by Marijuana Moment.







